Circular 18 December 2024: Criteria for Emicizumab use as Routine Prophylaxis in the Management of Patients with Haemophilia A with Factor VIII Inhibitors
The National Essential Medicines List Committee (NEMLC) has approved the inclusion of emicizumab as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adults and children with severe haemophilia A (congenital factor VIII deficiency) with factor VIIl inhibitors, as a special access medicine on the Tertiary and Quaternary Level Essential Medicines List (EML). ¹
The National Essential Medicines List Committee (NEMLC) has approved the inclusion of emicizumab as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adults and children with severe haemophilia A (congenital factor VIII deficiency) with factor VIIl inhibitors, as a special access medicine on the Tertiary and Quaternary Level Essential Medicines List (EML).¹ A guidance document outlining the criteria for the special access use has been developed.2